A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11

FOLFOXIRI plus bevacizumab is considered a standard initial therapy for metastatic colorectal cancer (mCRC). However, few prospective trials have evaluated triplet therapy plus bevacizumab in patients with RAS mutant mCRC. Patients with an age of 20 to 75 years, and unresectable, measurable tumors h...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Satake, Hironaga, Sunakawa, Yu, Miyamoto, Yuji, Nakamura, Masato, Nakayama, Hiroshi, Shiozawa, Manabu, Makiyama, Akitaka, Kobayashi, Kazuma, Kubota, Yutaro, Mori, Misuzu, Kotaka, Masahito, Takagane, Akinori, Gotoh, Masahiro, Takeuchi, Masahiro, Fujii, Masashi, Ichikawa, Wararu, Sekikawa, Takashi
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2018
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5922357/
https://ncbi.nlm.nih.gov/pubmed/29721163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24702
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars